Skip to main content
SpringerLink
Log in
Book cover

PET in Clinical Oncology pp 325–334Cite as

Metastatic bone disease

  • Chapter

  • 149 Accesses

Abstract

Bone metastases are common in the most prevalent cancers in Western Europe and the USA. Carcinomas of the breast (45-85%), prostate (33-85%) and lung (33-50%) are most commonly associated with metastatic bone disease. Bone metastases are also very common in renal carcinoma (33-40%) and follicular thyroid cancer (28-60%). After primary diagnosis of metastatic bone disease the average length of survival is reported 20 months for breast cancer, 17 months for prostate cancer and only a few months for lung cancer [21].

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Algra PR, Heimans JJ, Valk J, Nauta JJ, Lachniet M, Van Kooten (1992) Do metastases in vertebrae begin in the body or the pedicles? Imaging study in 45 patients. Am J Roentgenol 158:1275–1279

    CAS  Google Scholar 

  2. Batson OV (1995) The function of the vertebral veins and their role in the spread of metastases. Clin Orthop 312:4–9

    PubMed  Google Scholar 

  3. Blau M (1972) 18F-Fluoride for bone imaging. Semin Nucl Med 21:31–33

    Google Scholar 

  4. Bury T, Barreto A, Daenen F, Barthelemy N, Ghaye B, Rigo P (1998) Fluorine-18 deoxyglucose positron emission tomography for detection of bone metastases in patients with non-small cell lung cancer. Eur J Nucl Med 25:1244–1247

    Article  PubMed  CAS  Google Scholar 

  5. Cook GJ, Houston S, Rubens R, Maisey MN, Fogelman I (1998) Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol 16:3375–3379

    PubMed  CAS  Google Scholar 

  6. Creutzig H, Creutzig A, Gerdts KG, Greif E, Eckhardt W (1975) Vergleichende Untersuchungen mit osteotropen Radiopharmaka. I. Tierexperimentelle Untersuchungen zur Anreicherung von 18F, 85Sr and 99mTc-EHDP. Fortschr Röntgenstr 123:137–143

    Article  CAS  Google Scholar 

  7. Creutzig H (1975) Verleichende Untersuchungen mit osteotropen Radiopharmaka. II. Plasmaclearance von18F and 99mTc-EHDP. Fortschr Röntgenstr 123:313–318

    Article  CAS  Google Scholar 

  8. Creutzig H (1975) Vergleichende Untersuchungen mit osteotropen Radiopharmaka. III. Szintigraphie mit 18F and 99mTc-EHDP bei malignen and nicht malignen Erkrankungen. Fortschr Röntgenstr 123:462–467

    Article  CAS  Google Scholar 

  9. Frank JA, Ling A, Patronas NJ, Carrasquillo JA, Horvath K, Hickey AM, Dwyer AJ (1990) Detection of malignant bone tumors: MR imaging vs scintigraphy. Amer J Roentgenol 155:1043–1048

    CAS  Google Scholar 

  10. Gosfield E, Alavi A, Kneeland B (1993) Comparison of radionuclide bone scans and magnetic resonance imaging in detecting spinal metastases. J Nucl Med 34:2191–2198

    PubMed  Google Scholar 

  11. Green D, Jeremy R, Towson J, Morris J (1973) The role of fluorine 18 scanning in the detection of skeletal metastases in early breast cancer. Aust N Z J Surg 43:251–254

    Article  PubMed  CAS  Google Scholar 

  12. Hoh CK, Hawkins RA, Dahlbom M, Glaspy JA, Seeger LL, Choi Y, Schiepers CW, Huang SC, Satyamurthy N, Barrio JR, Phelps ME (1993) Whole body skeletal imaging with [18F] fluoride ion and PET. J Comput Assist Tomogr 17:34–41

    Article  PubMed  CAS  Google Scholar 

  13. Kosuda S, Kaji T, Jokawa H et al. (1996) Does bone SPECT actually have a lower sensitivity for detecting vertebral metastases than MRI? J Nucl Med 37:975–978

    PubMed  CAS  Google Scholar 

  14. Krasnow AZ, Hellman RS, Timins ME (1997) Diagnostic bone scanning in oncology. Semin Nucl Med 27:107–141

    Article  PubMed  CAS  Google Scholar 

  15. Moog F, Bangerter M, Kotzerke J, Guhlmann A, Frickhofen N, Reske SN (1998) 18-Ffluorodeoxyglucose-positron-emission tomography as a new approach to detect lymphomatous bone marrow. J Clin Oncol 16:603–609

    PubMed  CAS  Google Scholar 

  16. Munz DL (1994) Ist die Skelettszintigraphie zum Metastasenscreening noch erforderlich? Nuklearmedizin 32.5–10

    Google Scholar 

  17. Orr FW, Sanchez OH, Kostenuik P, Singh G (1995) Tumor interactions in skeletal metastasis. Clin Orthop 312:19–33

    PubMed  Google Scholar 

  18. Petren-Mallmin M (1994) Clinical and experimental imaging of breast cancer metastases in the spine. Acta Radiol Suppl 391:1–23

    PubMed  CAS  Google Scholar 

  19. Petren-Mallmin M, Andreasson I, Ljunggren O, Ahlstrom H, Bergh J, Antonini G, Langstrom B, Bergstrom M (1998) Skeletal metastases from breast cancer: uptake of 18-fluoride measured with positron emission tomography in correlation with CT. Skeletal Radiol 27:72–76

    Article  PubMed  CAS  Google Scholar 

  20. Reske SN, Karstens JH, Glöckner WM, Ammon J, Bull U (1990) Nachweis des Knochenmarksbefalls beim Mammakarzinom and bei malignen Lymphomen durch Immunszintigraphie des hämatopoetischen Knochenmarks. Fortschr Röntgenstr 152:60–66

    Article  CAS  Google Scholar 

  21. Rubens RD, Fogelman I (1991) Bone Metastases. Springer, London Berlin Heidelberg New York Tokio Hongkong

    Book  Google Scholar 

  22. Schirrmeister H, Rentschler M, Diederichs CG, Kotzerke J, Reske SN (1998) Darstellung des normalen Skelettsystems mit 18FNa-PET im Vergleich zur konventionellen Skelettszintigraphie. Fortschr Röntgenstr 168:451–456

    Article  CAS  Google Scholar 

  23. Schirrmeister H, Diederichs CG, Rentschler M, Kotzerke J, Reske SN (1998) Die Positronenemissionstomographie des Skelettsystems mit 18FNa: Häufigkeit, Befundmuster und Verteilung benigner Veränderungen. Fortschr Röntgenstr 169:310–314

    Article  CAS  Google Scholar 

  24. Schirrmeister H, Guhlmann CA, Elsner K, Nüssle K, Träger J, Kotzerke J, Reske SN (1999) Die Positronenemissionstomographie des Skelettsystems mit 18FNa: Häufigkeit, Befundmuster und Verteilung von Skelettmetastasen. Röntgenpraxis 52:19–25

    PubMed  CAS  Google Scholar 

  25. Schirrmeister H, Guhlmann CA, Diederichs CG, Träger H, Reske SN (1999) Planar bone imaging vs. 18F-PET in patients with cancer of the prostate, thyroid and lung. J Nucl Med 40:1623–1629

    PubMed  CAS  Google Scholar 

  26. Schirrmeister H, Guhlmann CA, Kotzerke J, Santjohanser C, Kühn T, Kreienberg R, Messer P, Nüssle K, Elsner K, Glatting G, Träger H, Neumaier B, Diederichs CD, Reske SN (1999) Early detection and accurate description of extent of metastatic bone disease in breast cancer with 18F-fluoride ion and positron emission tomography. J Clin Oncol 17:2381–2389

    PubMed  CAS  Google Scholar 

  27. Shreve PD, Grossman HB, Gross MD, Wahl RL (1996) Metastatic prostate cancer: Initial findings of PET with 2-deoxy-2[F-18]fluoro-D-glucose. Radiology 199:751–756

    PubMed  CAS  Google Scholar 

  28. Silberstein ER, Saenger EL, Tofe AJ, Alexander GW, Park HM (1973) Imaging of bone metastases with 99mTc-Sn-HEDP (diphosphonate), 18F and skeletal radiography. Radiology 107:551–555

    PubMed  CAS  Google Scholar 

  29. Traill Z, Richards MA, Moore N (1995) Magnetic resonance imaging of metastatic bone disease. Clin Orthop 312:76–88

    PubMed  Google Scholar 

  30. Venz S, Hosten N, Friedrichs R, Neumann K, Nagel R, Felix R (1994) Osteoplastische Knochenmetastasen beim Prostatakarzinom: Magnetresonanztomographie und Knochenmarkszintigraphie. Fortschr Röntgenstr 161:64–69

    Article  CAS  Google Scholar 

  31. Weber DA, Keyes JW, Landmann S, Wilson GA (1974) Comparison of Tc-polyphosphate and F18 for bone imaging. Am J Roentgen Rad Ther Nucl Med 121:184–190

    CAS  Google Scholar 

  32. Wilson MA, Calhoun FW (1981) The distribution of skeletal metastases in breast and pulmonary cancer: concise communication. J Nucl Med 22:594–597

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. H. Schirrmeister
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Bundeswehrzentralkrankenhaus Koblenz, Abteilung XV - Nuklearmedizin, Rübenacher Straße 170, Koblenz, 56072, Germany

    H. J. Wieler

  2. Division of Nuclear Medicine, Department of Radiology, DUMC 3949, Room 1419, Duke North Erwin Road, Durham, NC, 27710, USA

    R. Edward Coleman M.D. (Professor of Radiology, Vice-Chairman, Director) (Professor of Radiology, Vice-Chairman, Director)

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Schirrmeister, H. (2000). Metastatic bone disease. In: Wieler, H.J., Coleman, R.E. (eds) PET in Clinical Oncology. Steinkopff, Heidelberg. https://doi.org/10.1007/978-3-642-57703-1_25

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-57703-1_25

  • Publisher Name: Steinkopff, Heidelberg

  • Print ISBN: 978-3-642-63329-4

  • Online ISBN: 978-3-642-57703-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation